Literature DB >> 11486039

Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability.

X Lu1, G Magrane, C Yin, D N Louis, J Gray, T Van Dyke.   

Abstract

We examined the selective pressure for, and the impact of, p53 inactivation during epithelial tumor evolution in a transgenic brain tumor model. In TgT(121) mice, cell-specific inactivation of the pRb pathway in brain choroid plexus epithelium initiates tumorigenesis and induces p53-dependent apoptosis. We previously showed that p53 deficiency accelerates tumor growth due to diminished apoptosis. Here we show that in a p53(+/-) background, slow-growing dysplastic tissue undergoes clonal progression to solid angiogenic tumors in all animals. p53 is inactivated in all progressed tumors, with loss of the wild-type allele occurring in 90% of tumors. Moreover, similar progression occurs in 38% of TgT(121)p53(+/+) mice, also with loss of at least one p53 allele and inactivation of p53. Thus, the selective pressure for p53 inactivation, likely based on its apoptotic function, is high. Yet, in all cases, p53 inactivation correlates with progression beyond apoptosis reduction, from dysplasia to solid vascularized tumors. Hence, p53 suppresses tumor progression in this tissue by multiple mechanisms. Previous studies of fibroblasts and hematopoietic cells show that p53 deficiency can be associated with chromosomal instability, a mechanism that may drive tumor progression. To determine whether genomic gains or losses are present in tumors that progress in the absence of p53, we performed comparative genomic hybridization analysis. Surprisingly, the only detectable chromosomal imbalance was partial or complete loss of chromosome 11, which harbors the p53 gene and is thus the selected event. Flow cytometry confirmed that the majority of tumor cells were diploid. These studies indicate that loss of p53 function is frequent under natural selective pressures and furthermore that p53 loss can facilitate epithelial tumor progression by a mechanism in addition to apoptosis reduction and distinct from chromosomal instability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11486039      PMCID: PMC87319          DOI: 10.1128/MCB.21.17.6017-6030.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  74 in total

1.  Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery.

Authors:  H Offer; R Wolkowicz; D Matas; S Blumenstein; Z Livneh; V Rotter
Journal:  FEBS Lett       Date:  1999-05-07       Impact factor: 4.124

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 3.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

4.  Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2.

Authors:  H Lee; A H Trainer; L S Friedman; F C Thistlethwaite; M J Evans; B A Ponder; A R Venkitaraman
Journal:  Mol Cell       Date:  1999-07       Impact factor: 17.970

Review 5.  The p53 pathway.

Authors:  C Prives; P A Hall
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

Review 6.  Mouse models dissect the role of p53 in cancer and development.

Authors:  G Lozano; G Liu
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

Review 7.  p53-dependent cell cycle control: response to genotoxic stress.

Authors:  D Schwartz; V Rotter
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

8.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.

Authors:  A J Wagner; J M Kokontis; N Hay
Journal:  Genes Dev       Date:  1994-12-01       Impact factor: 11.361

9.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

Authors:  X Xu; K U Wagner; D Larson; Z Weaver; C Li; T Ried; L Hennighausen; A Wynshaw-Boris; C X Deng
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

10.  Cooperative tumorigenic effects of germline mutations in Rb and p53.

Authors:  B O Williams; L Remington; D M Albert; S Mukai; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

View more
  20 in total

1.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function.

Authors:  Huaxin Si; Erle S Robertson
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma.

Authors:  Jun Wang; Diana M Merino; Nicholas Light; Brian L Murphy; Yong-Dong Wang; Xiaohui Guo; Andrew P Hodges; Lianne Q Chau; Kun-Wei Liu; Girish Dhall; Shahab Asgharzadeh; Erin N Kiehna; Ryan J Shirey; Kim D Janda; Michael D Taylor; David Malkin; David W Ellison; Scott R VandenBerg; Charles G Eberhart; Rosalie C Sears; Martine F Roussel; Richard J Gilbertson; Robert J Wechsler-Reya
Journal:  Cancer Res       Date:  2019-03-18       Impact factor: 12.701

3.  Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population.

Authors:  Subramaniam Mohana Devi; Vellingiri Balachandar; Meyyazhagan Arun; Shanmugam Suresh Kumar; Balasubramanian Balamurali Krishnan; Keshavarao Sasikala
Journal:  Dig Dis Sci       Date:  2012-10-02       Impact factor: 3.199

4.  p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.

Authors:  Dawn Tolbert; Xiangdong Lu; Chaoying Yin; Mathew Tantama; Terry Van Dyke
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

5.  Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice.

Authors:  Lauren M Brubaker; Elizabeth Bullitt; Chaoying Yin; Terry Van Dyke; Weili Lin
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

6.  A mouse model of human oral-esophageal cancer.

Authors:  Oliver G Opitz; Hideki Harada; Yasir Suliman; Ben Rhoades; Norman E Sharpless; Ralph Kent; Levy Kopelovich; Hiroshi Nakagawa; Anil K Rustgi
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 7.  Telomeres, stem cells, senescence, and cancer.

Authors:  Norman E Sharpless; Ronald A DePinho
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

8.  Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss.

Authors:  Michael T Debies; Shelley A Gestl; Jessica L Mathers; Oliver R Mikse; Travis L Leonard; Susan E Moody; Lewis A Chodosh; Robert D Cardiff; Edward J Gunther
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

9.  Computer-assisted measurement of vessel shape from 3T magnetic resonance angiography of mouse brain.

Authors:  E Bullitt; S R Aylward; T Van Dyke; W Lin
Journal:  Methods       Date:  2007-09       Impact factor: 3.608

10.  Inactivation of gadd45a sensitizes epithelial cancer cells to ionizing radiation in vivo resulting in prolonged survival.

Authors:  Xiangdong Lu; Chunyu Yang; Reginald Hill; Chaoyin Yin; M Christine Hollander; Albert J Fornace; Terry Van Dyke
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.